Concepedia

Publication | Closed Access

Patient Preference for Dosing Frequency Based on Prior Biologic Experience.

13

Citations

0

References

2017

Year

Mingliang Zhang, Chureen Carter, William H. Olson, Michael P. Johnson, Susan K Brennem, Seina Lee, Kamyar Farahi
PubMed

Abstract

The least frequent dosing interval was preferred among biologic naïve patients and patients who had any experience with ustekinumab. Dosing interval may influence the shared decision-making process for psoriasis treatment with biologics. <em>J Drugs Dermatol. 2017;16(3):220-226.</em> .